Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6229 -0.0032 (-0.51%) Market Cap: 160.21 Mil Enterprise Value: 56.80 Mil PE Ratio: 0 PB Ratio: 2.12 GF Score: 64/100

Q1 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript

May 12, 2023 / 12:00PM GMT
Release Date Price: $1.37 (+0.74%)
Operator

Hello. Welcome to Adaptimmune's First Quarter Call and Business Update. I would now like to turn the call over to Juli Miller. Juli, please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - VP of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our first quarter 2023 financial results and business updates. I would ask you to review the full text of our forward-looking statements from this morning's press release.

We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer, is here with me for the prepared portion of the call. Other members of our management team will be available for Q&A. With that, I'll turn it over to Adrian Rawcliffe. Ad?

Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Thank you, Juli, and thanks to everyone for joining the call.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot